HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Policy

Pfizer settles with 2 generic Vyndamax makers in latest twist to ATTR market: analysts

Eleventh-hour settlements with two of the three generic drugmakers involved could bode well for both Pfizer and its ATTR competitor BridgeBio, analysts say.

By FiercePharma · Apr 29, 2026 · via FiercePharma
Pfizer settles with 2 generic Vyndamax makers in latest twist to ATTR market: analysts

Image: FiercePharma

This is an aggregated industry headline. Read the full story at FiercePharma →

Tags
policyformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Policy
All Policy →
FDA unveils plan for real-time review of clinical trial data, with AstraZeneca and Amgen already on board
PolicyFierceBiotech ↗
FDA unveils plan for real-time review of clinical trial data, with AstraZeneca and Amgen already on board
The FDA today announced a new initiative to allow its reviewers to access information from clinical trials in …
Apr 29, 2026
PolicyAJMC ↗
…
Apr 28, 2026
PolicySTAT News ↗
STAT+: Supreme Court to hear case about ‘skinny labeling’ and generic access
The Supreme Court Wednesday will hear oral arguments about a simmering controversy over so-called skinny label…
Apr 28, 2026